Drugs / HS-10352
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05504213 | Jan 2022 → Jul 2023 | breast cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04631835 | Sep 2020 → Apr 2023 | breast cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06788197 | Mar 2025 → Mar 2028 expected | breast cancer | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10352 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04631835 ↗ |
| Action | Inhibit | “HS-10352 is a highly potent and selective small molecule inhibitor of phosphoinositide 3-kinase (p110α).” NCT04631835 ↗ |
| Modality | Small molecule | “HS-10352 is a highly potent and selective small molecule inhibitor of phosphoinositide 3-kinase (p110α).” NCT04631835 ↗ |
| Route | Oral | “HS-10352 was administered orally once-daily (QD) at dose levels of 2, 4, 6, and 8 mg.” PMID 38037839 ↗ Dec 2023 |